Total Payments
$599,049
2024 Payments
$41,598
Companies
28
Transactions
1,111
Medicare Patients
6,436
Medicare Billing
$527,140
Payment Breakdown by Category
Other$485,209 (81.0%)
Travel$50,421 (8.4%)
Consulting$33,961 (5.7%)
Food & Beverage$29,200 (4.9%)
Education$257.83 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $485,209 | 228 | 81.0% |
| Travel and Lodging | $50,421 | 149 | 8.4% |
| Consulting Fee | $33,961 | 27 | 5.7% |
| Food and Beverage | $29,200 | 691 | 4.9% |
| Education | $257.83 | 16 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $230,894 | 273 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $177,529 | 349 | $0 (2024) |
| Mylan Specialty L.P. | $59,349 | 110 | $0 (2024) |
| Grifols USA, LLC | $47,090 | 96 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $36,241 | 78 | $0 (2019) |
| PFIZER INC. | $26,428 | 43 | $0 (2021) |
| Janssen Pharmaceuticals, Inc | $15,954 | 15 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $1,388 | 46 | $0 (2024) |
| Grifols Shared Services North America, Inc. | $820.00 | 1 | $0 (2023) |
| Regeneron Healthcare Solutions, Inc. | $747.92 | 24 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $41,598 | 153 | Mylan Specialty L.P. ($15,610) |
| 2023 | $82,008 | 144 | GlaxoSmithKline, LLC. ($35,265) |
| 2022 | $86,565 | 120 | GlaxoSmithKline, LLC. ($53,348) |
| 2021 | $55,234 | 82 | GlaxoSmithKline, LLC. ($29,767) |
| 2020 | $77,722 | 102 | GlaxoSmithKline, LLC. ($48,984) |
| 2019 | $136,822 | 194 | GlaxoSmithKline, LLC. ($61,669) |
| 2018 | $58,335 | 170 | Boehringer Ingelheim Pharmaceuticals, Inc. ($36,669) |
| 2017 | $60,764 | 146 | Boehringer Ingelheim Pharmaceuticals, Inc. ($20,519) |
All Payment Transactions
1,111 individual payment records from CMS Open Payments — Page 1 of 45
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $8.51 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 12/18/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $25.35 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/13/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $13.11 | General |
| Category: RESPIRATORY | ||||||
| 12/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | GLASSIA (Biological) | Food and Beverage | In-kind items and services | $21.47 | General |
| Category: IMMUNOLOGY | ||||||
| 12/06/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $19.24 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $18.20 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $23.48 | General |
| Category: Respiratory | ||||||
| 11/22/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $24.87 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/21/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,603.25 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 11/21/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Travel and Lodging | In-kind items and services | $495.59 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 11/21/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | Cash or cash equivalent | $124.99 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 11/20/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $29.61 | General |
| Category: HFCWO | ||||||
| 11/14/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $25.97 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 11/08/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $29.12 | General |
| Category: Respiratory | ||||||
| 11/07/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $97.52 | General |
| Category: Immunology | ||||||
| 11/05/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $21.15 | General |
| Category: IMMUNOLOGY | ||||||
| 10/30/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/30/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $15.67 | General |
| Category: RESPIRATORY | ||||||
| 10/29/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $23.94 | General |
| Category: Respiratory | ||||||
| 10/28/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $21.32 | General |
| Category: Respiratory | ||||||
| 10/25/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $21.11 | General |
| Category: Immunology | ||||||
| 10/22/2024 | Insmed, Inc. | Arikayce (Drug) | Education | In-kind items and services | $16.24 | General |
| Category: Respiratory | ||||||
| 10/21/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $20.17 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 10/17/2024 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,140.00 | General |
| Category: Pulmonology | ||||||
| 10/17/2024 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $118.41 | General |
| Category: Pulmonology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 1,478 | 1,808 | $246,310 | $113,830 |
| 2022 | 11 | 1,343 | 1,663 | $236,470 | $112,928 |
| 2021 | 12 | 1,805 | 2,189 | $330,275 | $158,553 |
| 2020 | 11 | 1,810 | 2,101 | $302,907 | $141,830 |
Total Patients
6,436
Total Services
7,761
Medicare Billing
$527,140
Procedure Codes
44
All Medicare Procedures & Services
44 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 84 | 222 | $96,570 | $36,911 | 38.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 432 | 592 | $59,240 | $36,700 | 62.0% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 245 | 245 | $20,580 | $8,838 | 42.9% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 224 | 224 | $18,593 | $8,092 | 43.5% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 251 | 251 | $22,088 | $6,581 | 29.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 48 | 63 | $9,765 | $5,872 | 60.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 128 | 142 | $8,676 | $5,391 | 62.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 41 | 43 | $6,493 | $3,708 | 57.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 14 | 14 | $2,142 | $960.52 | 44.8% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 11 | 12 | $2,163 | $777.24 | 35.9% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 94 | 215 | $93,525 | $36,240 | 38.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 446 | 570 | $57,020 | $35,331 | 62.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 72 | 126 | $19,530 | $9,818 | 50.3% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2022 | 168 | 168 | $14,046 | $6,852 | 48.8% |
| 94726 | Test to determine lung volumes using sensors | Office | 2022 | 157 | 157 | $12,970 | $5,968 | 46.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 145 | 155 | $9,455 | $5,759 | 60.9% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2022 | 172 | 172 | $15,085 | $4,767 | 31.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 44 | 44 | $6,644 | $4,323 | 65.1% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 21 | 22 | $3,983 | $1,699 | 42.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 12 | 22 | $2,376 | $1,218 | 51.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 12 | 12 | $1,836 | $952.88 | 51.9% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 106 | 328 | $142,680 | $56,408 | 39.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 460 | 558 | $55,805 | $36,435 | 65.3% |
| 94729 | Measurement of lung diffusing capacity | Office | 2021 | 335 | 335 | $28,140 | $15,019 | 53.4% |
| 94726 | Determination of lung volumes using plethysmography | Office | 2021 | 288 | 288 | $23,904 | $12,105 | 50.6% |
About Dr. Nashat Rabadi, MD
Dr. Nashat Rabadi, MD is a Critical Care Medicine healthcare provider based in Buffalo, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1669421970.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nashat Rabadi, MD has received a total of $599,049 in payments from pharmaceutical and medical device companies, with $41,598 received in 2024. These payments were reported across 1,111 transactions from 28 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($485,209).
As a Medicare-enrolled provider, Rabadi has provided services to 6,436 Medicare beneficiaries, totaling 7,761 services with total Medicare billing of $527,140. Data is available for 4 years (2020–2023), covering 44 distinct procedure/service records.
Ad
Practice Information
- Specialty Critical Care Medicine
- Other Specialties Pulmonary Disease
- Location Buffalo, NY
- Active Since 05/06/2006
- Last Updated 12/08/2021
- Taxonomy Code 207RC0200X
- Entity Type Individual
- NPI Number 1669421970
Products in Payments
- TRELEGY ELLIPTA (Drug) $168,191
- OFEV (Drug) $49,898
- Yupelri (Drug) $41,991
- Prolastin-C Liquid (Biological) $37,239
- ELIQUIS (Drug) $26,413
- LONHALA MAGNAIR (Drug) $20,014
- YUPELRI (Drug) $17,358
- XARELTO (Drug) $15,954
- UTIBRON (Drug) $11,371
- Prolastin-C (Biological) $10,671
- ANORO ELLIPTA (Drug) $9,322
- ANORO (Drug) $3,809
- BROVANA (Drug) $2,609
- Utibron (Drug) $2,247
- STIOLTO RESPIMAT (Drug) $1,622
- DUPIXENT (Biological) $1,007
- AIRSUPRA (Drug) $687.36
- NUCALA (Biological) $597.65
- ACTHAR (Biological) $347.28
- BREZTRI (Drug) $342.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Critical Care Medicine Doctors in Buffalo
Dr. Francois Fadell, M.d, M.D
Critical Care Medicine — Payments: $4,467
Critical Care Medicine $4,467
Kumar Shah, Md, MD
Critical Care Medicine — Payments: $2,553
Critical Care Medicine $2,553
Alberto Monegro, M.d, M.D
Critical Care Medicine — Payments: $1,847
Critical Care Medicine $1,847
Ann Steinwald, Np, NP
Critical Care Medicine — Payments: $1,495
Critical Care Medicine $1,495
Jessica Miller, Pa-C, PA-C
Critical Care Medicine — Payments: $1,328
Critical Care Medicine $1,328
Lucy Campbell, Md, MD
Critical Care Medicine — Payments: $195.92
Critical Care Medicine $195.92